

**SUPPLEMENTARY TABLE 1** Chemotherapy regimens<sup>a</sup> (cisplatin stratum, mITT population)

Chemotherapy regimen	Arm, n (%)	
	APF530 500 mg SC (n = 124)	Ondansetron 0.15 mg/kg IV (n = 128)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + gemcitabine	31 (25.0)	37 (28.9)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + pemetrexed	24 (19.4)	25 (19.5)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> )	22 (17.7)	22 (17.2)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + docetaxel	13 (10.5)	13 (10.2)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + vinorelbine	8 (6.5)	6 (4.7)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + irinotecan	4 (3.2)	4 (3.1)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + paclitaxel	4 (3.2)	4 (3.1)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + etoposide	2 (1.6)	3 (2.3)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + doxorubicin + methotrexate + vinblastine	2 (1.6)	2 (1.6)
Bevacizumab + cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + paclitaxel	1 (0.8)	2 (1.6)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + doxorubicin	3 (2.4)	0
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + gemcitabine + rituximab	1 (0.8)	2 (1.6)
Cetuximab + cisplatin ( $\geq 50$ mg/m <sup>2</sup> )	1 (0.8)	1 (0.8)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + cyclophosphamide ( $< 1500$ mg/m <sup>2</sup> ) + doxorubicin	0	2 (1.6)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + epirubicin + fluorouracil	1 (0.8)	1 (0.8)
Cyclophosphamide ( $< 1500$ mg/m <sup>2</sup> ) + docetaxel + doxorubicin	1 (0.8)	1 (0.8)
Bevacizumab + cisplatin ( $\geq 50$ mg/m <sup>2</sup> )	1 (0.8)	0
Bleomycin + dacarbazine + doxorubicin + vinblastine	0	1 (0.8)
Cisplatin ( $< 50$ mg/m <sup>2</sup> )	1 (0.8)	0
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + cyclophosphamide ( $< 1500$ mg/m <sup>2</sup> )	1 (0.8)	0
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + docetaxel + fluorouracil	1 (0.8)	0
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + doxorubicin + vinblastine	0	1 (0.8)
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + fluorouracil	1 (0.8)	0
Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) + gemcitabine + investigational drug	1 (0.8)	0
Cyclophosphamide ( $< 1500$ mg/m <sup>2</sup> ) + doxorubicin	0	1 (0.8)

IV, intravenously; mITT, modified intent-to-treat; SC, subcutaneously

<sup>a</sup>The 5 patients with no cisplatin or cisplatin ( $< 50$  mg/m<sup>2</sup>) were randomized under the stratum 'cisplatin regimen  $\geq 50$  mg/m<sup>2</sup>, yes' but actually received a different chemotherapy regimen.